1SAN.MI
Strong BuyFull HouseSanofi · Healthcare · France · $95.1B cap · $200K/day traded
EUR 79.90 +4.8% · close 30 Oct · scored 3 Nov
StockRank up 2.2 since 31 Oct: Momentum up 4.
Full House: Strong business, sensible price, and the market agrees.
Read our full research report on 1SAN.MI (Jun 2026), freeAs of 3 Nov 2026, MoatMap's StockRank for Sanofi (1SAN.MI) is 93/100, ranked against 24,000+ stocks in 35 markets (Quality 60, Value 74, Momentum 62, each scored against its sector).
Does StockRank work? Each month we publish how each tenth of the ranking did, whichever way it went. See the record →
ABOUT SANOFI
Read
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.6B | 41.6B | 44.3B | 46.7B | 4.8% | 48.8B | 51.0B | 54.3B | 7.8% |
| EPS (EUR) | 5.37 | 4.31 | 4.59 | 6.40 | 6.0% | 3.45 | — | — | — |
| Shares | 1.3B | 1.3B | 1.3B | 1.2B | -4.2% | 1.2B | — | — | — |
| Debt | 21.2B | 18.4B | 17.9B | 20.3B | -1.4% | 23.5B | — | — | — |
| Equity | 74.8B | 74.0B | 77.5B | 71.4B | -1.5% | — | — | — | — |
| Op CF | 10.5B | 10.3B | 9.1B | 10.8B | 0.7% | 11.8B | — | — | — |
| Inv CF | -2.1B | -6.2B | -4.4B | -2.4B | — | — | — | — | — |
| Fin CF | -5.8B | -8.1B | -5.8B | -8.2B | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Calmer than 80% of stocks we rank over the past year (volatility 26% a year).
How this is worked out
StockRank weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 1SAN.MI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 1SAN.MI | Sanofi(you) | $95.1B | 93 | Strong Buy |
| GSK | GSK plc | $101.7B | 89 | Strong Buy |
| BMY | Bristol-Myers Squibb Company | $125.6B | 96 | Strong Buy |
| NOVO-B.CO | Novo Nordisk A/S | $172.0B | 88 | Strong Buy |
| 4578.T | Otsuka Holdings Co., Ltd. | $41.6B | 92 | Strong Buy |
| GILD | Gilead Sciences, Inc. | $193.5B | 88 | Strong Buy |
| 1AMGN.MI | Amgen Inc. | $217.3B | 96 | Strong Buy |
| PFE | Pfizer Inc. | $171.2B | 84 | Strong Buy |
| 4519.T | Chugai Pharmaceutical Co., Ltd. | $71.3B | 76 | Buy |
| BAYN.DE | Bayer Aktiengesellschaft | $48.4B | 80 | Strong Buy |
Peer medians: ROE 2.7% · P/E 23.0x · Gross margin 53.7%
Company Deep Dive
Read the full report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.